# ACSM2A

## Overview
The ACSM2A gene encodes the enzyme acyl-CoA synthetase medium chain family member 2A, which is a member of the adenylate-forming enzyme superfamily. This enzyme is primarily involved in the activation of medium-chain fatty acids by converting them into acyl-CoA thioesters, a critical step for their subsequent degradation via β-oxidation in mitochondria. This process is essential for energy production and maintaining lipid homeostasis within cells (Kochan2009Structural). Additionally, ACSM2A plays a role in the glycine conjugation pathway, contributing to the metabolism and detoxification of various substrates, including xenobiotics (van2018Analyses). The protein is predominantly expressed in the liver and localized to mitochondria, highlighting its importance in liver metabolism and detoxification processes (Boomgaarden2009Comparative). Structural studies reveal that ACSM2A adopts a two-domain fold, with conformational changes that are crucial for its catalytic activity (Kochan2009Structural).

## Structure
The ACSM2A protein adopts a two-domain fold, consisting of a large N-terminal domain (residues 33-459) and a small C-terminal domain (residues 466-569), connected by a linker region. The active site is located at the interface of these domains, which is crucial for its catalytic function (Kochan2009Structural). The protein can adopt two main conformations: thioester-forming and adenylate-forming, which are related by a 135° rotation of the C-domain. These conformations influence the enzyme's catalytic steps, specifically thioesterification and adenylation (Kochan2009Structural).

The N-domain contains a hydrophobic pocket that accommodates substrates like butyryl-CoA and ibuprofen, contributing to substrate specificity (Kochan2009Structural). The protein's structure includes a Gly-rich P-loop and a conserved Arg472-Glu365 salt bridge, which are involved in domain rearrangement and ATP binding (Kochan2009Structural). Lys557 and a magnesium ion play critical roles in coordinating ATP pyrophosphates, essential for enzymatic activity (Kochan2009Structural).

ACSM2A is part of the adenylate-forming enzyme superfamily, showing structural homology with other members despite limited sequence conservation (Kochan2009Structural). The protein's structure and dynamics provide insights into its conformation-dependent catalysis and substrate preference.

## Function
The ACSM2A gene encodes a medium-chain acyl-CoA synthetase, which is part of the superfamily of adenylate-forming enzymes. This enzyme plays a crucial role in the activation of medium-chain fatty acids, such as butyric to decanoic acids, by converting them into acyl-CoA thioesters. This conversion is essential for the subsequent degradation of these fatty acids via β-oxidation in mitochondria, a process vital for energy production and maintaining cellular lipid homeostasis (Kochan2009Structural). 

ACSM2A is also involved in the glycine conjugation pathway, which is important for the metabolism and detoxification of various substrates, including xenobiotics like benzoate and salicylate. In this pathway, ACSM2A activates these substrates to acyl-CoA, which are then conjugated to glycine by glycine N-acyltransferase (GLYAT) (van2018Analyses). The enzyme's activity is characterized by a two-step reaction involving the formation of an acyl-adenylate intermediate, followed by the production of an acyl-CoA ester (Kochan2009Structural). 

ACSM2A is predominantly expressed in the liver, indicating its significant role in liver metabolism and detoxification processes (van2018Analyses). The protein's mitochondrial localization further underscores its involvement in cellular energy metabolism (Boomgaarden2009Comparative).

## Clinical Significance
The ACSM2A gene has been implicated in various metabolic disorders due to its role in fatty acid metabolism and detoxification processes. Mutations in ACSM2A, such as the Leu513Ser polymorphism, have been associated with risk factors for metabolic syndrome, including obesity, hypertension, and impaired glucose metabolism in Caucasian populations (Lindner2006The). This polymorphism is linked to higher postprandial triglyceride and glucose levels, suggesting a potential connection to insulin resistance (Lindner2006The).

In the context of drug metabolism, ACSM2A polymorphisms have been studied for their influence on the adverse effects of valproic acid (VPA) in epilepsy patients. Although mutations in ACSM2A did not directly correlate with VPA-related liver dysfunction, they were associated with variations in liver enzyme levels, indicating a potential impact on drug metabolism (Wang2017Association).

Additionally, genetic variants in ACSM2A have been linked to altered concentrations of tryptophan metabolites, which may affect host-microbe interactions and influence dietary-induced changes in health (Koshiba2020Identification). These findings underscore the clinical significance of ACSM2A in metabolic health and its potential role in drug metabolism and dietary interactions.


## References


[1. (Kochan2009Structural) Grazyna Kochan, Ewa S. Pilka, Frank von Delft, Udo Oppermann, and Wyatt W. Yue. Structural snapshots for the conformation-dependent catalysis by human medium-chain acyl-coenzyme a synthetase acsm2a. Journal of Molecular Biology, 388(5):997–1008, May 2009. URL: http://dx.doi.org/10.1016/j.jmb.2009.03.064, doi:10.1016/j.jmb.2009.03.064. This article has 95 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2009.03.064)

[2. (van2018Analyses) Rencia van der Sluis. Analyses of the genetic diversity and protein expression variation of the acyl: coa medium-chain ligases, acsm2a and acsm2b. Molecular Genetics and Genomics, 293(5):1279–1292, June 2018. URL: http://dx.doi.org/10.1007/s00438-018-1460-3, doi:10.1007/s00438-018-1460-3. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00438-018-1460-3)

[3. (Boomgaarden2009Comparative) Inka Boomgaarden, Christina Vock, Maja Klapper, and Frank Döring. Comparative analyses of disease risk genes belonging to the acyl-coa synthetase medium-chain (acsm) family in human liver and cell lines. Biochemical Genetics, 47(9–10):739–748, July 2009. URL: http://dx.doi.org/10.1007/s10528-009-9273-z, doi:10.1007/s10528-009-9273-z. This article has 36 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10528-009-9273-z)

[4. (Wang2017Association) Can Wang, Ping Wang, Li-ping Yang, Jing Pan, Xue Yang, and Hong-ying Ma. Association of cyp2c9, cyp2a6, acsm2a, and cpt1a gene polymorphisms with adverse effects of valproic acid in chinese patients with epilepsy. Epilepsy Research, 132:64–69, May 2017. URL: http://dx.doi.org/10.1016/j.eplepsyres.2017.02.015, doi:10.1016/j.eplepsyres.2017.02.015. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.eplepsyres.2017.02.015)

[5. (Koshiba2020Identification) Seizo Koshiba, Ikuko N. Motoike, Daisuke Saigusa, Jin Inoue, Yuichi Aoki, Shu Tadaka, Matsuyuki Shirota, Fumiki Katsuoka, Gen Tamiya, Naoko Minegishi, Nobuo Fuse, Kengo Kinoshita, and Masayuki Yamamoto. Identification of critical genetic variants associated with metabolic phenotypes of the japanese population. Communications Biology, November 2020. URL: http://dx.doi.org/10.1038/s42003-020-01383-5, doi:10.1038/s42003-020-01383-5. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s42003-020-01383-5)

[6. (Lindner2006The) Inka Lindner, Diana Rubin, Ulf Helwig, Inke Nitz, Jochen Hampe, Stefan Schreiber, Jürgen Schrezenmeir, and Frank Döring. The l513s polymorphism in medium‐chain acyl‐coa synthetase 2 (macs2) is associated with risk factors of the metabolic syndrome in a caucasian study population. Molecular Nutrition &amp; Food Research, 50(3):270–274, March 2006. URL: http://dx.doi.org/10.1002/mnfr.200500241, doi:10.1002/mnfr.200500241. This article has 20 citations.](https://doi.org/10.1002/mnfr.200500241)